| BioCryst Initiates Phase II Influenza Clinical Trial To Evaluate Peramivir |
|
|
|
|
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has initiated a Phase II clinical trial of peramivir, the company's lead influenza neuraminidase inhibitor, to determine the safety and efficacy of an intramuscular formulation of the drug in patients with influenza. [click link for full article] Read more at: http://www.medicalnewstoday.com/medicalnews.php?newsid=61668&nfid=rssfeeds. |